The ClinicianThe ClinicianКлиницист1818-83382412-8775Publishing House ABV Press10810.17650/1818-8338-2011-3-86-94PHARMACOTHERAPYФАРМАКОТЕРАПИЯDISSEMINATED NON SMALL-CELL LUNG CANCER: POSSIBILITIES OF DRUG THERAPY IN THE FIRST DECADE OF THE XXI CENTURYДИССЕМИНИРОВАННЫЙ НЕМЕЛКОКЛЕТОЧНЫЙ РАК ЛЕГКОГО: ВОЗМОЖНОСТИ ЛЕКАРСТВЕННОЙ ТЕРАПИИ В ПЕРВОЙ ДЕКАДЕ XXI ВЕКАGarinA. M.ГаринА. М.
Russian Federation
NasyrovaR. Yu.НасыроваР. Ю.
Russian Federation
r.nasyrova@mail.ruN.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical SciencesРОНЦ им. Н.Н. Блохина РАМН150720115386941707201417072014Copyright ©; 2011, Garin A.M., Nasyrova R.Y.Copyright ©; 2011, Гарин А.М., Насырова Р.Ю.2011Garin A.M., Nasyrova R.Y.Гарин А.М., Насырова Р.Ю.https://creativecommons.org/licenses/by/4.0https://klinitsist.abvpress.ru/Klin/article/view/108

In the review the data on the incidence of lung cancer in Russia and the world is presented. Effectiveness of different screening methods used to identify patients with lung cancer, the value of different diagnostic methods is discussed. The data on the current drug therapy of non small-cell lung cancer , built on the basis of doublets of cisplatin and carboplatin used in the first line therapy, as well as on the doublets without cisplatin or carboplatin, generally used in the second line therapy and target therapies which are prescribed separately or in combination with chemotherapy. Indicated the efficiency of certain chemotherapy regimens, data on one-year, sometimes two-year survival, median survival, the major toxicity of combinations, doses, drugs and detailed diagrams of their prescription.

В обзоре представлены данные о распространенности рака легкого (РЛ) в РФ и мире. Обсуждается эффективность различных скрининговых методик, применяемых для выявления больных РЛ, ценность различных диагностических методов. Представлены данные о современной лекарственной терапии немелкоклеточного РЛ, построенной на основе дуплетов цисплатина и карбоплатина, используемых в 1-й линии терапии, а также дуплетов, не содержащих цисплатин или карбоплатин, обычно применяемых во 2-й линии терапии, и таргетных препаратов, назначаемых раздельно или в комбинации с химиотерапией. Указана эффективность отдельных режимов химиотерапии, приведены данные об одно-, иногда двухгодичной выживаемости, медианы выживаемости, основные проявления токсичности комбинаций, дозы лекарств и подробные схемы их назначения.

lung cancernon small-cell lung cancerscreeningspiral computed tomographytreatment of metastatic non small-cell lung cancercisplatincarboplatinрак легкогонемелкоклеточный рак легкогоскринингспиральная компьютерная томографиялечение диссеминированного немелкоклеточного рака легкогоцисплатинкарбоплатин1. Haddadin S., Perry M.C. History of small-cell lung cancer. Clin Lung Cancer 2011;12:2;87–93.Haddadin S., Perry M.C. History of small-cell lung cancer. Clin Lung Cancer 2011;12:2;87–93.2. Rosenblatt M.B. Lung cancer in the 19th century. Bull Hist Med 1964;38:395–25.Rosenblatt M.B. Lung cancer in the 19th century. Bull Hist Med 1964;38:395–25.3. Morriston Davies H. Recent advances in the surgery of the lung and pleura. Br J Surg 1913;1(2):228–58.Morriston Davies H. Recent advances in the surgery of the lung and pleura. Br J Surg 1913;1(2):228–58.4. Horn L., Johnson D.H., Evarts A. Graham and the first pneumonectomy for lung cancer. J Clin Oncol 2008;26:3268–75.Horn L., Johnson D.H., Evarts A. Graham and the first pneumonectomy for lung cancer. J Clin Oncol 2008;26:3268–75.5. Doll R., Hill A.B. Smoking and carcinoma of the lung preliminary report. BMJ 1950;2:739–48.Doll R., Hill A.B. Smoking and carcinoma of the lung preliminary report. BMJ 1950;2:739–48.6. Parkin D.M., Bray F., Ferlay J., Pisani P. Global Cancer Statistics, 2002. CA 2003;55:74–108.Parkin D.M., Bray F., Ferlay J., Pisani P. Global Cancer Statistics, 2002. CA 2003;55:74–108.7. Аксель Е.М., Давыдов М.И. Заболеваемость злокачественными новообразованиями населения России и стран СНГ в 2008 году. Вестник РОНЦ им. Н.Н. Блохина РАМН 2010;21(2):52–86.Аксель Е.М., Давыдов М.И. Заболеваемость злокачественными новообразованиями населения России и стран СНГ в 2008 году. Вестник РОНЦ им. Н.Н. Блохина РАМН 2010;21(2):52–86.8. Berlin N.I., Buncher C.R., Fontana R.S. et al. The National Cancer Institute Cooperative Early Lung Cancer Detection Program: results of the initial screen (prevalence): early lung cancer detection:Berlin N.I., Buncher C.R., Fontana R.S. et al. The National Cancer Institute Cooperative Early Lung Cancer Detection Program: results of the initial screen (prevalence): early lung cancer detection:introduction. Am Rev Respir Dis 1984;130:545–9.9. Fontana R.S., Sanderson D.R., Woolner L.B. et al. Screening for lung cancer. A critique of the Mayo Lung Project. Cancer 1991;67(4 Suppl):1155–64.Fontana R.S., Sanderson D.R., Woolner L.B. et al. Screening for lung cancer. A critique of the Mayo Lung Project. Cancer 1991;67(4 Suppl):1155–64.10. Melamed M.R., Flehinger B.J., Zaman M.B. et al. Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New York. Chest 1984;86(1):44–53.Melamed M.R., Flehinger B.J., Zaman M.B. et al. Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New York. Chest 1984;86(1):44–53.11. Eguchi K., Henschke C. Meeting Summary of the 12th International Conference on Screening for Lung Cancer: Nara, Japan, April 2005. J Thorac Oncol 2006;1:190–7.Eguchi K., Henschke C. Meeting Summary of the 12th International Conference on Screening for Lung Cancer: Nara, Japan, April 2005. J Thorac Oncol 2006;1:190–7.12. Karnofsky D.A., Craven L.F., Burchenal J.A. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948;1:634–51.Karnofsky D.A., Craven L.F., Burchenal J.A. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948;1:634–51.13. Lung Cancer. Dana-Farber Cancer Institute. A. Skarin, P. Lorigan, eds. Elsevier, 2007.Lung Cancer. Dana-Farber Cancer Institute. A. Skarin, P. Lorigan, eds. Elsevier, 2007.14. Bonomi P., Kim K., Fairclough D., et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J ClinBonomi P., Kim K., Fairclough D., et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J ClinOncol 2000;18(3):623–31.15. Rossel R., Gatzemeier U., Betticher D.C., et al. Phase III randomized trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 2002;13(10):1539–49.Rossel R., Gatzemeier U., Betticher D.C., et al. Phase III randomized trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 2002;13(10):1539–49.16. Shiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346(2):92–8.Shiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346(2):92–8.17. Fossela F., Pereira J.R., von Pawel J., et al. Randomized multinational phase III study of docetaxel +Fossela F., Pereira J.R., von Pawel J., et al. Randomized multinational phase III study of docetaxel +platinum combinations versus vinorelbin plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003;21(16):3016–27.18. Sandler A.B., Nemunaitis J., Denham C., et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. AnnSandler A.B., Nemunaitis J., Denham C., et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. AnnOncol 2000;18:122–30.19. Wozniak A.J., Crowley J.J., Balcerzak S.P., et al. Randomized trial comparing cisplatin + cisplatin plus vinorelbin in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998;16(17):2459.Wozniak A.J., Crowley J.J., Balcerzak S.P., et al. Randomized trial comparing cisplatin + cisplatin plus vinorelbin in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998;16(17):2459.20. Nagao K.A., Fukuoka M, Fujita A, et al. A phase II study of irinotecan combined with cisplatin in non-small cell lung cancer. CPT-11 Lung Cancer Study Group. Gan To Kagaku Ryoho 2000;27(3):413–21.Nagao K.A., Fukuoka M, Fujita A, et al. A phase II study of irinotecan combined with cisplatin in non-small cell lung cancer. CPT-11 Lung Cancer Study Group. Gan To Kagaku Ryoho 2000;27(3):413–21.21. Kelly K., Granley J., Bunn P.A. Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbin plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19(13):3210–8.Kelly K., Granley J., Bunn P.A. Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbin plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19(13):3210–8.22. Pallis A.G., Syrigos K., Kotsakis A. et al. Second-line paclitaxel/carboplatin versus vinorelbin/carboplatin in the patients who have advanced non-small-cell lung cancer pretreated with non-platinum based chemotherapy: a multicenter randomized phase II study. Clin Lung CancerPallis A.G., Syrigos K., Kotsakis A. et al. Second-line paclitaxel/carboplatin versus vinorelbin/carboplatin in the patients who have advanced non-small-cell lung cancer pretreated with non-platinum based chemotherapy: a multicenter randomized phase II study. Clin Lung Cancer2011;12(2):100–9.;12(2):100–9.23. Herbst R.S., Langer C.J. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol 2002;29(1 Suppl4):27–36.Herbst R.S., Langer C.J. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol 2002;29(1 Suppl4):27–36.24. Sederholm C., Hillerdal G., Lamberg K., et al. Phase III trial of gemcitabine plus carboplatin versus gemcitabine alone in metastatic NSCLC: the Swedish lung cancer croup. J Clin Oncol 2005;23:8380–8.Sederholm C., Hillerdal G., Lamberg K., et al. Phase III trial of gemcitabine plus carboplatin versus gemcitabine alone in metastatic NSCLC: the Swedish lung cancer croup. J Clin Oncol 2005;23:8380–8.25. Cancer – matrix manual. 5th edition – a multidisciplinary. E.H. Lin, R. Losano, eds. Advanced Medical Pub Inc, 2010.Cancer – matrix manual. 5th edition – a multidisciplinary. E.H. Lin, R. Losano, eds. Advanced Medical Pub Inc, 2010.26. Kosmas C., Tsavaris N., Vadiaka M., et al. Gemcitabine and docetaxel as second-line chemotherapy for patients with non-small-cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens. Cancer 2001;92(11):2902–10.Kosmas C., Tsavaris N., Vadiaka M., et al. Gemcitabine and docetaxel as second-line chemotherapy for patients with non-small-cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens. Cancer 2001;92(11):2902–10.27. Muñoz A., Rubio I., Mañé J.M., et al. Phase II study of docetaxel/vinorelbine in patients with non-small-cell-lung cancer previously treated with platinumbased chemotherapy. Clin Lung CancerMuñoz A., Rubio I., Mañé J.M., et al. Phase II study of docetaxel/vinorelbine in patients with non-small-cell-lung cancer previously treated with platinumbased chemotherapy. Clin Lung Cancer2002;4(3):168–73.;4(3):168–73.28. Azzoli C.G., Baker S. Jr., Temin S., et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009;27(36):6251–66.Azzoli C.G., Baker S. Jr., Temin S., et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009;27(36):6251–66.29. Beretta G. Mitomycin C.: fifty years’ medical experience. Turin: Edizioni Minerva Medica, 2004.Beretta G. Mitomycin C.: fifty years’ medical experience. Turin: Edizioni Minerva Medica, 2004.30. Руководство по химиотерапии опухолевых заболеваний. Под ред. Н.И. Переводчикова. М.: Практическая медицина, 2011.Руководство по химиотерапии опухолевых заболеваний. Под ред. Н.И. Переводчикова. М.: Практическая медицина, 2011.31. Katakani N., Nishimura T., Sigiura T. et al. Vinorelbin plus gemcitabine in the treatment of chemotherapy naive stage IIIB/IV non-small-cell lung cancer. Available from: http://www.asco.org/ascov2/Meetings/Abstracts?vmview=abst_detail_view&confID=10&abstractID=2773Katakani N., Nishimura T., Sigiura T. et al. Vinorelbin plus gemcitabine in the treatment of chemotherapy naive stage IIIB/IV non-small-cell lung cancer. Available from: http://www.asco.org/ascov2/Meetings/Abstracts?vmview=abst_detail_view&confID=10&abstractID=277332. Dassonville O., Bozec A., Fischel J.L., Milano G. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinas inhibitors. Similarities and differences. Grit Rev Oncol Hemat 2007;62(1):53–61.Dassonville O., Bozec A., Fischel J.L., Milano G. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinas inhibitors. Similarities and differences. Grit Rev Oncol Hemat 2007;62(1):53–61.33. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].J Clin Oncol 2003;21(12):2237–46.34. Perer-Soler R., Chachoua A., Hammond L.A., et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22(16):3238–47.Perer-Soler R., Chachoua A., Hammond L.A., et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22(16):3238–47.35. Thatcher N., Chang A., Parikh P., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer). LancetThatcher N., Chang A., Parikh P., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet2005;366(9496):1527–37.;366(9496):1527–37.36. Stewart D.J. Targeted therapy in nonsmall cell lung cancer. In: Targeted Cancer Therapy. Kurzrock R. and Markman M. eds. Humana Press, 2008.Stewart D.J. Targeted therapy in nonsmall cell lung cancer. In: Targeted Cancer Therapy. Kurzrock R. and Markman M. eds. Humana Press, 2008.37. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542–50. Eur Heart J 2009;30(19):2369–413.Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542–50. Eur Heart J 2009;30(19):2369–413.